{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:11:49Z","timestamp":1771920709887,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study explored whether integrating innovative immunotherapies targeting costimulatory or co-inhibitory pathways beyond standard PD-1, PD-L1, and CTLA-4 treatments affects hepatic adverse events. We further analyzed liver-related side effects in patients with cancer receiving these novel therapies alone or in combination with others.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical studies on immunotherapies targeting molecules such as LAG-3, TIGIT, TIM-3, VISTA, CD47, ICOS, CD40, and B7-H3 were retrieved from PubMed, Embase, Cochrane Library, and Web of Science. Data from eligible studies that reported liver-related adverse events until May 2024 were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis included 63 studies involving 7,327 patients. Among these, randomized controlled trials demonstrated that adding LAG-3 or TIGIT inhibitors to established therapies did not increase the risk of elevated hepatic enzyme levels or hepatitis. CD27-CD70-targeted monotherapy showed a strong association with elevated transaminase levels. Dual therapies combining 4-1BB agonists with PD-1\/PD-L1 inhibitors resulted in &amp;gt;15% all-grade transaminase elevation, whereas CD40 agonists paired with immunotherapy resulted in &amp;gt;4% high-grade elevations. Immunotherapy-chemotherapy combinations showed high transaminase elevation rates. Overall, the incidence of elevated liver enzyme levels was similar between the single-agent and dual immunotherapy groups. The addition of chemotherapy or targeted therapy to single-agent immunotherapy increases the incidence of adverse events associated with elevated liver enzyme levels. The incidence of liver enzyme adverse events continued to increase with the addition of immunotherapy to the combination regimens. Cholestatic enzyme elevations were prominent in CD27-CD70 monotherapy and CD40 agonist combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This meta-analysis suggests adding LAG-3 or TIGIT inhibitors to existing therapies may not significantly increase hepatic toxicity. It reviewed adverse events from novel immunotherapies alone or combined with PD-1\/PD-L1\/CTLA-4 inhibitors, targeted agents, or chemotherapy. These findings have important clinical implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1677998","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:01:27Z","timestamp":1768204887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Minyan","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinuo","family":"Dong","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Diseases, National Health Commission (NHC) Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Diseases, National Health Commission (NHC) Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University","place":["Shanghai, China"]},{"name":"Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fujian Clinical Research Center for Liver and Intestinal Diseases","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Diseases, National Health Commission (NHC) Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieting","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Diseases, National Health Commission (NHC) Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Diseases, National Health Commission (NHC) Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Lei","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Diseases, National Health Commission (NHC) Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Mao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Diseases, National Health Commission (NHC) Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Clinical Research Institute, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11363","DOI":"10.3390\/ijms231911363","article-title":"Challenges and future trends of hepatocellular carcinoma immunotherapy","volume":"23","author":"Rizzo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/biomedicines9020101","article-title":"Checkpoint inhibitors and hepatotoxicity","volume":"9","author":"Malnick","year":"2021","journal-title":"Biomedicines"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2017.04.003","article-title":"Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: hemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors","volume":"72","author":"Alessandrino","year":"2017","journal-title":"Clin Radiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and me-ta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264327","article-title":"Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors","volume":"14","author":"Roy","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.esmoop.2022.100639","article-title":"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"7","author":"Garralda","year":"2022","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2023.04.010","article-title":"Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis","volume":"188","author":"Boutros","year":"2023","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","article-title":"Anti-TIGIT therapies for solid tumors: a systematic review","volume":"8","author":"Rousseau","year":"2023","journal-title":"ESMO Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"B15","article-title":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-Analyses","author":"Wells","year":"2014"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1085969","article-title":"Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"14","author":"Abdel-Rahman","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816636557","article-title":"Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"10","author":"Abdel-Rahman","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062679","article-title":"The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis","volume":"14","author":"Mei","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206375121250701073343","article-title":"The safety and efficacy of anti-LAG-3 for patients with melanoma: A systematic review and meta-analysis study","author":"Nejati","year":"2025","journal-title":"Anticancer Agents Med Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2019.09.009","article-title":"Immune checkpoint inhibitor-related luminal GI adverse events","volume":"90","author":"Kr\u00f6ner","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives","volume":"13","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1096\/fba.2021-00039","article-title":"OX40-targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice","volume":"3","author":"Tee","year":"2021","journal-title":"FASEB Bioadv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0779","DOI":"10.1136\/jitc-2020-0779-6corr1","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis","volume":"8","author":"Xing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.11.72","article-title":"Effectiveness and safety of PD-1\/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis","volume":"10","author":"Shen","year":"2018","journal-title":"J Thorac Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1032","article-title":"IFN\u03b3 and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma","volume":"6","author":"Long","year":"2016","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.010","article-title":"Exclusion of T cells from pancreatic carcinomas in mice is regulated by ly6C(low) F4\/80(+) extratumoral macrophages","volume":"149","author":"Beatty","year":"2015","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T-cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600146","article-title":"CSF-1R-dependent lethal hepatotoxicity patotoxicity when agonistic CD40 antibody is given before but not after chemotherapy","volume":"197","author":"Byrne","year":"2016","journal-title":"J Immuno"},{"key":"B39","doi-asserted-by":"publisher","first-page":"102514","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","volume":"114","author":"Regev","year":"2020","journal-title":"J Autoimmun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18271","article-title":"Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients","volume":"60","author":"Fettiplace","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"992","DOI":"10.14218\/JCTH.2025.00228","article-title":"Consensus on the management of liver injury associated with targeted drugs and immune checkpoint inhibitors for hepatocellular carcinoma (Version 2024)","volume":"13","author":"Zhao","year":"2025","journal-title":"J Clin Transl Hepatol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1788767","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1677998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:40:26Z","timestamp":1771911626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1677998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2025.1677998"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1677998","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1677998"}}